Stuart Gordon MDProfessor of Medicine, Wayne State University School of Medicine, Detroit, Michigan, and Director, Division of Hepatology, Henry Ford Health System, Detroit, Michigan
Dr. Gordon is Professor of Medicine, Wayne State University School of Medicine, Detroit, Michigan and Director, Division of Hepatology, Henry Ford Health System, Detroit, Michigan. He is a graduate of Wayne State University School of Medicine, Detroit, Michigan (MD) and received his training in clinical hepatology at University of Miami School of Medicine, Miami, Florida. His major research interests include the epidemiology and treatment of viral hepatitis, and the epidemiology and treatment of cholestatic liver disease. He authored or co-authored over 200 articles, 15 book chapters, 4 invited editorials and 1 textbook. His current H-index is 53. He is identified in the 2018 Highly Cited Researchers list from Clarivate Analytics. Dr. Gordon has served as an ad-hoc member of several NIH and NCI Study Sections and he is on the editorial board of Clinical Gastroenterology and Hepatology. Dr. Gordon was the recipient of the Distinguished Alumni Award from Wayne State University School of Medicine. He is currently an appointed member of the AASLD-IDSA Hepatitis C Guidance Committee. In collaboration with the Centers for Disease Control, Dr. Gordon is the Principal Investigator of the multicenter CHeCS (Chronic Hepatitis Cohort Study) that examines the health burden, natural history, epidemiology and treatment challenges posed by chronic viral hepatitis in the United States. He is also the Principal Investigator of the Fibrotic Liver Disease (FOLD) consortium of 11 US medical centers that collectively serve 4.2 million patients, and which examines the prevalence, natural history, treatment uptake/response, and clinical outcomes of patients with Primary Biliary Cholangitis (PBC) in the United States.
DisclosuresDr. Gordon receives research funding (to institution) from Gilead and AbbVie.
Recent Contributions to PracticeUpdate:
- Liver Stiffness After Antiviral HCV Treatment Independently Associated With Adverse Outcomes
- Baseline Cirrhosis Increases Risk of Hepatocellular Carcinoma Long After HCV Eradication
- Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct-Acting Antiviral Agents
- Effectiveness of Ledipasvir–Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response
- Accuracy of FibroScan vs Histology for Liver Fibrosis in HBV or HCV
- Short-Term Variations in Elastometry Measurements in Chronic Liver Disease